Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Amir Jazaeri, University of Virginia Identifier:
First received: September 7, 2004
Last updated: May 19, 2014
Last verified: May 2014
Results First Received: May 19, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Interventions: Biological: incomplete Freund's adjuvant
Biological: ovarian cancer peptide vaccine
Biological: sargramostim
Biological: tetanus toxoid helper peptide
Procedure: adjuvant therapy

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Single Arm No text entered.

Participant Flow:   Overall Study
    Single Arm

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Single Arm No text entered.

Baseline Measures
   Single Arm 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   7 
>=65 years   2 
[Units: Years]
Mean (Standard Deviation)
 57  (13) 
[Units: Participants]
Female   9 
Male   0 
Region of Enrollment 
[Units: Participants]
United States   9 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety of the Vaccine   [ Time Frame: Days 1,8,15,22,29,36,43,50 ]

2.  Primary:   Measure of Tumor-antigen-specific Immunity in SIN by ELIspot Assay   [ Time Frame: Day 22 ]

3.  Secondary:   Measure of Tumor-antigen-specific Immunity in PBMC by Elispot Assay   [ Time Frame: Days 1,8,15,22,29,36,43,50 and Month 3 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Craig L. Slingluff, MD
Organization: University of Virginia
phone: 434-924-1730

Responsible Party: Amir Jazaeri, University of Virginia Identifier: NCT00091273     History of Changes
Other Study ID Numbers: 11276
Study First Received: September 7, 2004
Results First Received: May 19, 2014
Last Updated: May 19, 2014